https://www.pnas.org/doi/10.1073/pnas.2220403120
"
Significance
There is an urgent need to develop a mucosal SARS-CoV-2 vaccine that can induce
broad, durable protection. MMR has been one of the safest and most successful
vaccines in human history. By expressing the six-proline-stabilized prefusion
spikes from three diverse SARS-CoV-2 strains in the MeV, MuV-JL1, and MuV-JL2
vaccine strains from MMR, we generated a MMS trivalent vaccine candidate.
Intranasally delivered MMS induced strong SARS-CoV-2-specific neutralizing
antibody, mucosal IgA, and systemic and lung resident T cell immune responses
that provide broad protection against challenge with each of these three
strains. Therefore, MMS is a highly promising next-generation vaccine candidate
against COVID-19. Furthermore, any of the three component vaccine viruses can
be quickly modified when a new important SARS-CoV-2 variant appears.
Abstract
As SARS-CoV-2 variants of concern (VoCs) that evade immunity continue to
emerge, next-generation adaptable COVID-19 vaccines which protect the
respiratory tract and provide broader, more effective, and durable protection
are urgently needed. Here, we have developed one such approach, a highly
efficacious, intranasally delivered, trivalent measles-mumps-SARS-CoV-2 spike
(S) protein (MMS) vaccine candidate that induces robust systemic and mucosal
immunity with broad protection. This vaccine candidate is based on three
components of the MMR vaccine, a measles virus Edmonston and the two mumps
virus strains [Jeryl Lynn 1 (JL1) and JL2] that are known to provide safe,
effective, and long-lasting protective immunity. The six proline-stabilized
prefusion S protein (preS-6P) genes for ancestral SARS-CoV-2 WA1 and two
important SARS-CoV-2 VoCs (Delta and Omicron BA.1) were each inserted into one
of these three viruses which were then combined into a trivalent “MMS”
candidate vaccine. Intranasal immunization of MMS in IFNAR1^−/− mice induced a
strong SARS-CoV-2-specific serum IgG response, cross-variant neutralizing
antibodies, mucosal IgA, and systemic and tissue-resident T cells. Immunization
of golden Syrian hamsters with MMS vaccine induced similarly high levels of
antibodies that efficiently neutralized SARS-CoV-2 VoCs and provided broad and
complete protection against challenge with any of these VoCs. This MMS vaccine
is an efficacious, broadly protective next-generation COVID-19 vaccine
candidate, which is readily adaptable to new variants, built on a platform with
a 50-y safety record that also protects against measles and mumps."
Via Diane A.
Cheers,
*** Xanni ***
--
mailto:xanni@xanadu.net Andrew Pam
http://xanadu.com.au/ Chief Scientist, Xanadu
https://glasswings.com.au/ Partner, Glass Wings
https://sericyb.com.au/ Manager, Serious Cybernetics
